-
Key Brands
-
Statistics
-
Revenue
-
Contribution
-
Market data
| Brand | Therapeutic category |
|---|---|
|
Arixtra |
Antithrombotic agent |
|
Diprivan |
General anaesthetic |
|
Fraxiparine |
Low molecular weight heparin |
|
Naropin |
Regional anaesthetic |
|
Ultiva |
Injectable general anaesthetic |
0
Products
Launched
Launched
(2022: 3)
Product
Recalls
Recalls
(2022: Nil)
10
%
Average Staff
Turnover
Turnover
(2022: 29%)
Work-related
Facilities
Facilities
(2022: Nil)
410
Sales
Representatives
Representatives
(2022: 535)
900
Permanent
Employees
Employees
(June 2022: 1,166)
| Revenue |
2023 R’million |
2022 (CER) R’million |
Change % |
|---|---|---|---|
|
Total Commercial Pharmaceuticals |
5 505 |
5 581 |
(1) |
|
Regional Brands |
737 |
677 |
9 |
|
Sterile Focus Brands |
4 768 |
4 904 |
(3) |
|
Manufacturing – FDF Other |
115 |
130 |
(12) |
|
Total |
5 620 |
5 711 |
(2) |
Note: Commercial Pharmaceuticals revenue is by customer geography and manufacturing revenue by place of manufacture.
Contribution to Group revenue (%)
- Rest of Group 86
- Asia 14
Revenue by segment (%)
- Sterile Focus Brands 85
- Regional Brands 13
- Manufacturing - FDF Other 2
- Aspen’s Diprivan holds 37,9% of the propofol market with growth of 4,7% from March 2022.
- Aspen Asia in-market sales excluding China grew 3,7% versus the market which grew at 2,5% over the prior year.
Source: China IMS CHPA Report, March 2023, IQVIA June 2023.
